# desmoid tumors FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/desmoid-tumors

> 3 upcoming FDA catalysts in desmoid tumors: zolucatetide (PBLS) on 1H 2027 (trial start); varegacestat (IMNM) on April 28, 2027 (PDUFA date); zolucatetide (PBLS) on 2029 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for desmoid tumors?

3 upcoming FDA catalysts in desmoid tumors: zolucatetide (PBLS) on 1H 2027 (trial start); varegacestat (IMNM) on April 28, 2027 (PDUFA date); zolucatetide (PBLS) on 2029 (topline data readout). SEC Form 10-Q: "We plan to initiate a global registrational Phase 3 trial for zolucatetide in patients with desmoid tumors in the first half of 2027 with topline results anticipated in 2029." [Calendar and source filings](https://sec-api.dev/indications/desmoid-tumors)

Source: SEC Form 10-Q, accession 0001193125-26-458388, https://www.sec.gov/Archives/edgar/data/1657677/000119312526458388/ck0001657677-20260930.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/indications/desmoid-tumors#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| late 2025 | [Varegacestat topline data readout](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | scheduled | "We particularly look forward to topline data in the second half of 2025 for the RINGSIDE trial of varegacestat, which we believe will demonstrate significant benefits for patients with desmoid tumors."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000110465925025558/tm259725d1_ex99-1.htm)) |
| December 15, 2025 | [Varegacestat topline data readout](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | completed, positive | "On December 15, 2025, Immunome, Inc. (the Company, we or our) announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), in patients with progressing desmoid tumors." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1472012/000119312525318429/d793961d8k.htm)) |
| 1H 2027 | [Zolucatetide trial start](https://sec-api.dev/pdufa/zolucatetide) | PBLS | desmoid tumors | scheduled | "We plan to initiate a global registrational Phase 3 trial for zolucatetide in patients with desmoid tumors in the first half of 2027 with topline results anticipated in 2029." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1657677/000119312526458388/ck0001657677-20260930.htm)) |
| April 28, 2027 | [Varegacestat PDUFA date](https://sec-api.dev/pdufa/varegacestat) | IMNM | desmoid tumors | scheduled | "Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526453556/imnm-ex99_1.htm)) |
| 2029 | [Zolucatetide topline data readout](https://sec-api.dev/pdufa/zolucatetide) | PBLS | desmoid tumors | scheduled | "We plan to initiate a global registrational Phase 3 trial for zolucatetide in patients with desmoid tumors in the first half of 2027 with topline results anticipated in 2029." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1657677/000119312526458388/ck0001657677-20260930.htm)) |

## Drugs

- [Varegacestat](https://sec-api.dev/pdufa/varegacestat) (IMNM)
- [Zolucatetide](https://sec-api.dev/pdufa/zolucatetide) (PBLS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/desmoid-tumors.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "desmoid tumors FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/desmoid-tumors

```bibtex
@misc{secapidev_indications_desmoid_tumors_20261116,
  title        = {desmoid tumors FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/desmoid-tumors}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_desmoid_tumors_20261116","title":"desmoid tumors FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/desmoid-tumors","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
